characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

characteristic: age

text: Highlands Oncology Group

text: not applicable

text: not provided

text: not provided

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Predose

text: not applicable

text: not provided

text: USA

text: not provided

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: male

text: whole blood

text: Human Whole Blood enitociclib treated-C2D1 Predose

text: Enitociclib


status: PUBLIC

text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

tag: attribute

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: pre-dosing control sample for SU-DHL-4 and SU-DHL-10 DLBCL cells were seeded 18 hours prior to treatment with one of three CDK9 inhibitors: VIP152 (0.25 or 1 μM), atuveciclib (1 μM), or KB-0742 (1 μM).

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: control

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-control 0hr

characteristic: title

text: control

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: SU-DHL-4 and SU-DHL-10 DLBCL cells were seeded 18 hours prior to treatment with either DMSO or one of three CDK9 inhibitors: VIP152 (0.25 or 1 μM), atuveciclib (1 μM), or KB-0742 (1 μM).

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 4hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 4hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito1 4hr

characteristic: title

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 4hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 4hr

text: KB


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-DMSO 5-6hr

characteristic: title

text: DMSO

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 5-6hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 5-6hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Atuve 5-6hr

characteristic: title

text: Atuve

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 5-6hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 5-6hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Enito250 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito250 5-6hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Enito1 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 5-6hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 5-6hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-KB 5-6hr

characteristic: title

text: KB

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 8hr

text: DMSO


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 8hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito1 8hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 8hr

text: Atuve


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 8hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-DMSO 12hr

characteristic: title

text: DMSO

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 12hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 12hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Atuve 12hr

characteristic: title

text: Atuve

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 12hr

text: KB


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 16-20hr

text: DMSO


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito250 16-20hr

characteristic: title

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 16-20hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 16-20hr

text: Atuve


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-KB 16-20hr

characteristic: title

text: KB

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 16-20hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Enito250 replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 16-20hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Enito1 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito1 16-20hr

characteristic: title

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 16-20hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 16-20hr

text: KB


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-DMSO 28-52hr

characteristic: title

text: DMSO

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito250 28-52hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 28-52hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Atuve 28-52hr

characteristic: title

text: Atuve

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-KB 28-52hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-DMSO 28-52hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Enito250 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-Enito250 28-52hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Enito1 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Enito1 28-52hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-4-Atuve 28-52hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-4-KB 28-52hr

characteristic: title

text: KB

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: control

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-control 0hr

text: control


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 4hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito250 4hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 4hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 4hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-KB 4hr

characteristic: title

text: KB

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 5-6hr

text: DMSO


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 5-6hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito1 5-6hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 5-6hr

text: Atuve


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 5-6hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-DMSO 5-6hr

characteristic: title

text: DMSO

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Enito250 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 5-6hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Enito1 replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 5-6hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Atuve 5-6hr

characteristic: title

text: Atuve

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 5-6hr

text: KB


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 8hr

text: DMSO


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito250 8hr

characteristic: title

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 8hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 8hr

text: Atuve


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-KB 8hr

characteristic: title

text: KB

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 12hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 12hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito1 12hr

characteristic: title

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 12hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 12hr

text: KB


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-DMSO 16-20hr

characteristic: title

text: DMSO

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 16-20hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 16-20hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Atuve 16-20hr

characteristic: title

text: Atuve

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 16-20hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: DMSO replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 16-20hr

text: DMSO


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Enito250 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito250 16-20hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Enito1 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 16-20hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Atuve replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 16-20hr

text: Atuve


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: KB replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-KB 16-20hr

characteristic: title

text: KB

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: DMSO

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-DMSO 28-52hr

text: DMSO


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 28-52hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Enito1 28-52hr

characteristic: title

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Atuve

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Atuve 28-52hr

text: Atuve


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: KB

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 28-52hr

text: KB


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: DMSO replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-DMSO 28-52hr

characteristic: title

text: DMSO

characteristic: treatment


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: Enito250 replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito250 28-52hr


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

characteristic: INSDC secondary accession

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

characteristic: dosing timepoint

text: Enito1 replicate 2

characteristic: drug treatment and replicate

text: not provided

characteristic: ethnicity

text: not applicable

text: not provided

text: not applicable

characteristic: isolate

text: not provided

characteristic: karyotype

text: Homo sapiens

characteristic: organism

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-Enito1 28-52hr


text: Vincerx Pharma

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: not applicable

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

text: not provided

text: not provided

text: not provided

text: Atuve replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

characteristic: phenotype

text: not provided

characteristic: population

text: not provided

characteristic: race

text: not provided

text: not applicable

characteristic: sex

text: not applicable

characteristic: tissue

text: SUDHL-10-Atuve 28-52hr

characteristic: title

text: Atuve

characteristic: treatment


characteristic: External Id

text: Vincerx Pharma

characteristic: INSDC center name

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: not applicable

characteristic: age

text: not applicable

text: not provided

text: not provided

text: not applicable

text: not provided

characteristic: description

text: not provided

text: not provided

characteristic: disease

text: not provided

text: KB replicate 2

text: not provided

text: not applicable

text: not provided

text: not applicable

text: not provided

text: Homo sapiens

text: not provided

text: not provided

text: not provided

text: not provided

text: not applicable

text: not applicable

text: SUDHL-10-KB 28-52hr

text: KB


text: University of Iowa

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

text: Pathogen.cl

text: missing

text: USA

text: Homo sapiens

characteristic: host

text: missing

characteristic: isolate

text: Wound-Foot

text: missing

text: Acinetobacter baumannii

characteristic: organism

text: Pathogen: clinical or host-associated sample from Acinetobacter baumannii


text: University of Iowa

text: live

text: Pathogen.cl

text: missing

text: USA

text: Homo sapiens

text: missing

text: Wound-Leg

text: missing

text: Acinetobacter baumannii

characteristic: title


text: University of Iowa

text: live

text: Pathogen.cl

text: missing

text: USA

text: Homo sapiens

text: missing

text: Fluid

text: missing

text: Pseudomonas aeruginosa

text: Pathogen: clinical or host-associated sample from Pseudomonas aeruginosa


text: University of Iowa

text: live

text: Pathogen.cl

text: missing

text: USA

text: Homo sapiens

text: missing

text: urine

text: missing

text: Acinetobacter baumannii


text: Banovich Lab, Integrated Cancer Genomics, TGen - Translational Genomics Research Institute

text: live

text: Generic

text: female

characteristic: Sex

text: High grade

characteristic: clinical diagnosis

text: missing

text: Non-HISPANIC WHITE

characteristic: ethnicity

text: FGFR2(Amplification); MYC(Amplification); TP53(V272L); KMT2C(G2464*); TMB-Low(1mut/Mb); MSS

characteristic: gemextra

text: missing

text: Homo sapiens

text: High grade Adenocarcinoma

characteristic: pathology

text: Moderate-High grade appendiceal adenocarcinoma

characteristic: pathology 2

text: The positive specimens show pools of mucin and floating clusters of tumor cells with poorly differentiated signet ring cell/goblet cell morphology.

characteristic: pathology 3

text: GCA

characteristic: pathology abbreviated

text: Goblet-cell adenocarcinoma

characteristic: pathology reviewed

text: Peritoneal metastasis

text: Cancerous

characteristic: status

text: Peritoneal metastasis

characteristic: tissue

text: L35150, GCA

text: ABCA3 (A1107T) Missense 6 AFF3 (A1134G) Missense 6 ANGPTL3 Deletion . ARID1B (R496K) Missense 10 ATF4 (I141V) Missense 8 BCAR3 (E772K) Missense 11 BEND4 (A126S) Missense 11 BMPR1B (F387C) Missense 10 C1orf43 Amplification . C1orf68 Amplification . CACNA1H (V869I) Missense 8 CBLN2 Amplification . CCDC74A (R149C) Missense 7 CCL21 (M87I) Missense 5 CHTOP Amplification . COG5 (E840Q) Missense 9 CRCT1 Amplification . CREB3L4 Amplification . CRNN Amplification . CRTC2 Amplification . DENND4B Amplification . DUSP8 Amplification . DUSP8 Breakpoint: Duplication . EXD1 (R112H) Missense 10 FAT3 (R4181H) Missense 10 FBXO46 (R470Q) Missense 7 GATAD2B Amplification . HAX1 Amplification . HIRIP3 (R526W) Missense 5 ILF2 Amplification . INTS3 Amplification . ITGB6 (K165I) Missense 7 IVL Amplification . JTB Amplification . KPRP Amplification . KRT28 (R311H) Missense 14 KRTAP5- 1 Amplification . KRTAP5- 2 Amplification . KRTAP5- 3 Amplification . KRTAP5- 4 Amplification . KRTAP5- 5 Amplification . LAMA1 (R162H) Missense 5 LCE1A Amplification . LCE1B Amplification . LCE1C Amplification . LCE1D Amplification . LCE1F Amplification . LCE2A Amplification . LCE2B Amplification . LCE2C Amplification . LCE3D Amplification . LCE3E Amplification . LCE5A Amplification . LCE6A Amplification . LOR Amplification . MEST (L144F) Missense 9 MKRN3 (S133L) Missense 8 MRPL23 Amplification . MRPL23/RP11- 723G8.2 Fused Genes (RNA) . MSTN (R88W) Missense 8 NHS (R373*) Stop Gain 8 NME8 (L581V) Missense 10 NOD2 (W157*) Stop Gain 10 NPR1 Amplification . NSMCE4A Amplification . NUP210L Amplification . OR10S1 (P331S) Missense 6 P2RY13 (V115A) Missense 10 PAX9 (A340V) Missense 7 PCDHGA5 (D557N) Missense 6 PGLYRP3 Amplification . PGLYRP4 Amplification . PLP1 (V267I) Missense 8 POU5F1B Amplification . PTPRJ (L176F) Missense 9 RAB13 Amplification . RBMXL3 (R434H) Missense 10 S100A1 Amplification . S100A13 Amplification . S100A14 Amplification . S100A16 Amplification . S100A2 Amplification . S100A3 Amplification . S100A4 Amplification . S100A5 Amplification . S100A7 Amplification . S100A7A Amplification . S100A8 Amplification . SACS (D829G) Missense 12 SDF4 (R98W) Missense 9 SLC27A3 Amplification . SLC30A3 (P216L) Missense 10 SLC39A1 Amplification . SLC7A10 (A126T) Missense 5 SLC9A6 (E671K) Missense 5 SLX4 (A267V) Missense 9 SMAD7 Amplification . SMAD7/CBLN2 Fused Genes (RNA) . SMCP Amplification . SNAPIN Amplification . SPRR1A Amplification . SPRR1B Amplification . SPRR2A Amplification . SPRR2B Amplification . SPRR2D Amplification . SPRR2E Amplification . SPRR2F Amplification . SPRR2G Amplification . SPRR3 Amplification . SPRR4 Amplification . SRRM4 (R382W) Missense 9 SV2C (G416R) Missense 10 SYNE1 (A4368S) Missense 5 TACC2 (L422R) Missense 5 TCERG1 (I983fs) Frameshift 13 TPM3 Amplification . TSHZ3 (R381W) Missense 5 TTC29 (N473K) Missense 11 TUBGCP4 (T660I) Missense 9 TYR (R278Q) Missense 6 UBAP2L Amplification . WDR47 (N354D) Missense 10 ZNF436 (D41V) Missense 9

characteristic: vus


characteristic: External Id

characteristic: INSDC center name

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Generic

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: male

characteristic: age

text: High grade

text: missing

text: Non-HISPANIC WHITE

text: TP53(M237I); TMB-Low(3mut/Mb); MSS

text: missing

text: Homo sapiens

text: High grade Adenocarcinoma

text: The immunohistochemical staining features are consistent with adenocarcinoma from gastrointestinal tract primary. Positive staining for synaptophysin and chromogranin raises the possibility of goblet cell adenocarcinoma from appendiceal primary.

text: GCA

text: Goblet-cell adenocarcinoma

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L35148, GCA

text: ATR (P1110L) AURKB (V103M) FGF10 (amplification) MET (amplification) MLL2 (Q3764H) PIK3C2G (amplification) PTPRO (amplification) RICTOR (amplification) SDHA (amplification) SMAD4 (R361G)


text: live

text: Generic

text: female

characteristic: Sex

text: Low grade

characteristic: clinical diagnosis

text: missing

text: Non-HISPANIC WHITE

characteristic: ethnicity

text: GNAS(R201H); KRAS(G13D); U2AF1(S34F); TMB-Low(<1mut/Mb); MSS

characteristic: gemextra

text: missing

text: Homo sapiens

characteristic: organism

text: Low grade Mucinous Neoplasm

characteristic: pathology

text: Low grade Mucinous Neoplasm

characteristic: pathology 2

text: Resected tissue is extensively involved by a neoplasm producing abundant mucin. The mucinous lining is relatively frequent (being present in almost every 2 x low power field) and shows morphological features ranging from bland columnar nuclei with abundant mucin to rounded high-grade nuclei associated with mitotic activity and architectural complexity. Although most of the tumor colonizes superficial peritoneum, invasion is present and best appreciated in sections from the uterus (block E4), stomach (block J2), colon (block B2) and ovary (block E8). Per WHO criteria, the mucinous neoplasm involving the peritoneum corresponds to an overall grade 2.

text: LAMN

text: Low-grade appendiceal mucinous neoplasm

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L35151, LAMN

characteristic: title

text: ADCY8 (R475C) Missense 7 CT47B1 Deletion . ESCO2 (T254fs) Frameshift 5 SPATA31A3 Deletion . SPATA31A6 Deletion . UGT1A8 Deletion .


characteristic: External Id

characteristic: INSDC center name

text: live

text: Generic

text: male

text: Low grade

text: missing

text: Non-HISPANIC WHITE

text: ARID2(R1677*); GNAS(R844H); U2AF1(S34F); TMB-LOW(<1mut/Mb); MSS-Stable

text: missing

text: Homo sapiens

text: Low grade Mucinous Neoplasm

text: Low grade Mucinous Neoplasm

text: There are rare foci of glandular epithelium showing more complex architecture and mitoses, raising the possibility of progression.

characteristic: pathology 3

text: LAMN

characteristic: pathology abbreviated

text: Low-grade appendiceal mucinous neoplasm

characteristic: pathology reviewed

text: Peritoneal metastasis

text: Cancerous

characteristic: status

text: Peritoneal metastasis

characteristic: tissue

text: L35144, LAMN

text: ADAMTS14 (F140S) Missense 6 ATP10A (L269P) Missense 5 CIT (D1070N) Missense 7 DSG1 (A195T) Missense 6 FNBP1 (R389H) Missense 6 GLI1 (R265W) Missense 6 LOXL2 (R98Q) Missense 5 TPH1 (R230C) Missense 6

characteristic: vus


characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Generic

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: female

characteristic: age

text: Low-grade Adenocarcinoma

text: missing

text: BLACK or AFRICAN-AMERICAN

text: GNAS(R201C); KRAS (G12D)

text: missing

text: Homo sapiens

text: Low grade Adenocarcinoma

text: Low grade appendiceal adenocarcinoma

text: Metastatic well-differentiated mucinous adenocarcinoma of the appendix.

text: LGMA

text: Low-grade mucinous adenocarcinoma

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L49296, LGMA

text: AC002398.9 (W36*) Stop Gain 7 NHS (P1452S) Missense 6 PSENEN (W36*) Stop Gain 7 TIAM1 (P940L) Missense 5 USP40 (Q1160fs) Frameshift 5


text: live

text: Generic

text: male

characteristic: Sex

text: Low grade Adenocarcinoma

characteristic: clinical diagnosis

text: missing

text: Non-HISPANIC WHITE

characteristic: ethnicity

text: GNAS(R201H); KRAS (G12D); Low (1mut/Mb), MSS

characteristic: gemextra

text: missing

text: Homo sapiens

characteristic: organism

text: low grade mucinous adenocarcinoma

characteristic: pathology

text: Low grade appendiceal adenocarcinoma

characteristic: pathology 2

text: LGMA

text: Low-grade mucinous adenocarcinoma

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: K28668, LGMA

characteristic: title

text: AHNAK2 (P3501L) Missense 5 AIRE (R494H) Missense 5 CASKIN2 (R217H) Missense 5 DYSF (T1870M) Missense 6 ELFN2 (T143M) Missense 5 GALNT1 (C497R) Missense 6 GATA4 (T280M) Missense 5 GRIN2A (R1316K) Missense 5 IGKV4- 1/IGKC Fused Genes (RNA) . KIF26B (V1113M) Missense 5 MXD3 (R148Q) Missense 5 NBPF3 (G281R) Missense 7 NUP88 (M332I) Missense 6 OVCH1 (L439F) Missense 7 PCDHA12 (S668L) Missense 6 PLD2 (R829W) Missense 6 PMEPA1 (C24Y) Missense 5 PRRG3 (R19H) Missense 11 SLC13A5 (V431M) Missense 5 ZNF521 (E454G) Missense 6 ZNF853 (L302F) Missense 5


characteristic: External Id

text: Banovich Lab, Integrated Cancer Genomics, TGen - Translational Genomics Research Institute

characteristic: INSDC center name

text: live

text: Generic

text: female

text: Low grade

text: missing

text: Non-HISPANIC WHITE

text: KRAS (G12V); TMB-Low(1mut/Mb); MSS

text: missing

text: Homo sapiens

text: Low grade Adenocarcinoma

text: Low grade appendiceal adenocarcinoma

text: Although the vast majority of the tumor mass is composed of mucin devoid of epithelial elements, islands of carcinoma with high-grade nuclear features as well as architectural complexity are multifocally seen, granting a diagnosis of adenocarcinoma.. The greatest amount of tumor is seen within blocks O1 and P1. Architectural complexity is appreciated in the B1. This addendum is issued to specify that the morphological features of the peritoneal metastases are those of a grade 2 mucinous adenocarcinoma (in light of the focal presence of high-grade cytological features and architectural complexity). The findings are concordant with the primary tumor (S20-07602), which was diagnosed as a well-differentiated (low grade) mucinous adenocarcinoma of the appendix

characteristic: pathology 3

text: LGMA

characteristic: pathology abbreviated

text: Low-grade mucinous adenocarcinoma

characteristic: pathology reviewed

text: Peritoneal metastasis

text: Cancerous

characteristic: status

text: Peritoneal metastasis

characteristic: tissue

text: L35147, LGMA

text: ADH1B (T374M) Missense 6 ADNP2 (V907I) Missense 17 AJAP1 (T376M) Missense 7 ALPP (A261V) Missense 8 ANGPTL3 Deletion . APBA2 (A207T) Missense 8 APOB (A4473T) Missense 7 BAI1 (R231C) Missense 9 BRCA2 (S3366fs) Frameshift 31 CNGA2 (Q626K) Missense 6 CNKSR1 (R556W) Missense 8 COL3A1/IGKC Fused Genes (RNA) . CTGF (E311K) Missense 5 DCBLD2 (V712M) Missense 6 DDAH2 (P73L) Missense 9 DDC8 (R212W) Missense 7 DST (R2291C) Missense 7 FOXJ1 (S9L) Missense 6 GRIA1 (R509Q) Missense 9 HNRNPH2 (T328fs) Frameshift 6 HSPA12B (V435M) Missense 6 KIAA0100 (R2092C) Missense 7 KIAA1549 (V553M) Missense 7 LRRC59 (L132W) Missense 7 MAOB (S2I) Missense 5 MTOR (R2505Q) Missense 8 NT5C1B (D378G) Missense 7 NT5C1B- RDH14 (D378G) Missense 7 NTM (N148T) Missense 9 OR13D1 (R86C) Missense 7 PTGIR (R229C) Missense 10 RNGTT (R574*) Stop Gain 8 SEZ6L (R861H) Missense 10 SHROOM4 (R722H) Missense 7 SMAD2 (S464*) Stop Gain 16 SMAD3 (S355*) Stop Gain 16 SOCS3 (V120L) Missense 8 UGDH (c.1037+1delG) Splice Donor Variant 8 ZFR2 (S178L) Missense 9 ZNF341 (P172R) Missense 8 ZNF583 (H342Q) Missense 7 MYT1L (E163del) Inframe Deletion 7

characteristic: vus


characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Generic

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: male

characteristic: age

text: Low grade

text: missing

text: Non-HISPANIC WHITE

text: CDKN1B(Deletion); GNAS(R201C); KRAS(G12D); TMB-Low(1mut/Mb); MSS-Stable

text: missing

text: Homo sapiens

text: Low grade Adenocarcinoma

text: Low grade appendiceal adenocarcinoma

text: Viable strips of carcinoma are relatively frequently seen and associated with extensive mucin. There is focal architectural complexity associated with mitotic and apoptotic activity.

text: LGMA

text: Low-grade mucinous adenocarcinoma

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L35146, LGMA

text: ARHGEF28 (P353L) Missense 5 BRDT (Q272H) Missense 5 BSN (R2595C) Missense 5 C1orf170 (G145C) Missense 5 C2orf91 (C18*) Stop Gain 6 C4B (R1072W) Missense 11 COL7A1 (A1313T) Missense 7 CSMD2 (R1555Q) Missense 5 CYP11A1 (S195L) Missense 6 DCBLD1 (S275L) Missense 7 DLGAP2 (P109L) Missense 7 EREG (R102*) Stop Gain 6 FGF10 (V123I) Missense 5 FRAS1 (Q2242H) Missense 5 GLB1L (G306E) Missense 5 GNB1L (A271T) Missense 5 GPC6 (G425W) Missense 6 GPR12 (A199V) Missense 6 GRM7 (T675M) Missense 5 HIST1H1C Deletion . HIST1H1E Deletion . HIST1H2AB Deletion . HIST1H2AI Deletion . HIST1H2AK Deletion . HIST1H2BB Deletion . HIST1H2BC Deletion . HIST1H2BD Deletion . HIST1H3D Deletion . HIST1H4E Deletion . HIST1H4H Deletion . HIST2H2AC Deletion . HIST2H2BE Deletion . JMY (R388*) Stop Gain 5 KCNQ3 (D556N) Missense 7 LRP1B (C1103Y) Missense 6 MXRA5 (T2697M) Missense 12 NDUFV2 (V134A) Missense 12 NOX5 (T707M) Missense 5 NYAP1 (T382M) Missense 9 OR10A6 (F211L) Missense 5 PCDHA9 (S601L) Missense 6 RBMXL3 (R379Q) Missense 11 SLC5A3 (Q442H) Missense 6 SRFBP1 (E306K) Missense 5 STAT6 (c.1001+1G>A) Splice Donor Variant 8 TAOK2 (A530V) Missense 5 TNN (R214H) Missense 11 TNN (V953M) Missense 9 TTN (I33593T) Missense 6 TXLNB (R237H) Missense 7 WDR36 (V836L) Missense 6 ZSCAN1 (R374H) Missense 6


text: live

text: Generic

text: female

characteristic: Sex

text: High grade Adenocarcinoma

characteristic: clinical diagnosis

text: missing

text: Non-HISPANIC WHITE

characteristic: ethnicity

text: TMB-Low(1mut/Mb); MSS

characteristic: gemextra

text: missing

text: Homo sapiens

characteristic: organism

text: High grade Adenocarcinoma

characteristic: pathology

text: High grade Adenocarcinoma

characteristic: pathology 2

text: Poorly-differentiated adenocarcinoma involving fibroconnective soft tissues

text: MHNA

text: Mod/High-grade Non-mucinous adenocarcinoma

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L49295, MHNA

characteristic: title

text: ADARB2 (R73H) Missense 10 ATP6V0D1 (N10K) Missense 9 BLVRA (L185F) Missense 10 CAMKK2 (R217W) Missense 7 CILP (R431C) Missense 8 COL16A1 (E1446K) Missense 9 DAAM2 (Q756H) Missense 7 DLG5 (P1918L) Missense 8 DNAH3 (N3022S) Missense 8 EMID1 (P330L) Missense 9 FAM173A (V68fs) Frameshift 9 FAN1 (R658Q) Missense 9 GABRA5 (M182I) Missense 9 HCLS1 (H473Y) Missense 8 IKBKAP (A1191V) Missense 9 KMT2B (R1140H) Missense 8 KRT33A (R75H) Missense 8 LRP1 (N2350S) Missense 11 MSN (R100H) Missense 7 MYO16 (A1317T) Missense 9 NBEAL1 (T624fs) Frameshift 7 NCR1 (A21T) Missense 9 NLRP10 (Y388*) Stop Gain 8 NLRP9 (L135F) Missense 9 OR2J3 (P141S) Missense 6 OR52E4 (R264H) Missense 9 PCNXL2 Breakpoint: Inversion . PEG3 (H1142Q) Missense 7 POLA1 (L742V) Missense 7 PPARD (Q408R) Missense 6 PROC (E98*) Stop Gain 10 SETD1B (E1061del) Inframe Deletion 8 SI (C63Y) Missense 8 SLC41A3 (A196P) Missense 5 TMEM247 (F198L) Missense 9 USH1G (R366C) Missense 10 WFS1 (A602V) Missense 8 ZFYVE26 (L1661del) Inframe Deletion 7


characteristic: External Id

characteristic: INSDC center name

text: live

text: Generic

text: female

text: High grade Adenocarcinoma

text: missing

text: HISPANIC WHITE

text: APC(R876*); FBXW7 (R278*); KRAS(G12D); PIK3CA (E545K); LOW (1mut/ Mb); MSS

text: missing

text: Homo sapiens

text: Metastatic adenocarcinoma, moderately to poorly differentiated

text: Moderate-High grade appendiceal adenocarcinoma

text: MHNA

characteristic: pathology abbreviated

characteristic: pathology reviewed

text: Peritoneal metastasis

text: Cancerous

characteristic: status

text: Peritoneal metastasis

characteristic: tissue

text: L42572, MHNA

text: ADAM8 (G65E) Missense 12 AKAP6 (E1835D) Missense 14 ARAP1 (R407W) Missense 14 ARMCX5 (S184F) Missense 14 ASB5 (D193Y) Missense 11 ATF7IP (R363*) Stop Gain 7 ATP11C Breakpoint: Duplication . BRWD3 (Q1134R) Missense 13 C2CD3 (L1594F) Missense 13 CBFA2T2 (P86L) Missense 14 COL5A2 (G309D) Missense 11 COL6A5 (R190W) Missense 14 CRY1 (R109*) Stop Gain 11 CTHRC1 (R146W) Missense 19 EMP1 (R123H) Missense 10 FAM19A1 (R57H) Missense 11 FXR1 (T611N) Missense 13 GAD2 (G60R) Missense 14 GCN1L1 (F2254L) Missense 13 GPR158 (S698I) Missense 12 GREB1 (V1233M) Missense 15 HECTD1 (D1185G) Missense 12 IRX5 (R269fs) Frameshift 11 KIF16B (R1015fs) Frameshift 9 LAMA5 (R2645C) Missense 11 LPAR4 (K38M) Missense 17 MAPK13 (K55E) Missense 8 MLK4 (A141T) Missense 35 MTMR8 (D687Y) Missense 16 NEDD1 (Y134*) Stop Gain 8 PCDHA3 (G430R) Missense 15 PGGT1B (G220V) Missense 16 PJA1 (R309fs) Frameshift 19 PKN3 (T130M) Missense 12 PMEPA1 (C24S) Missense 9 PRPF31 (A415P) Missense 14 RAI1 (E1380K) Missense 15 RAI1 (V692M) Missense 15 RGAG4 (A490T) Missense 13 SHC4 (F19Y) Missense 13 SHROOM4 (R593H) Missense 13 SLC25A44 (R249H) Missense 10 SLC6A15 (P682Q) Missense 15 SOGA2 (R976H) Missense 13 SPEG (R3196*) Stop Gain 9 SZT2 (P3231L) Missense 13 TBCD (Q723*) Stop Gain 13 TLN2 (S314P) Missense 12 TRANK1 (R2551K) Missense 12 TRPM4 (P1101L) Missense 12 TTC7A (A207T) Missense 10 TTN (K34569N) Missense 11 TTN (R24196H) Missense 14 WDR44 (E567K) Missense 11 WNT6 (R299C) Missense 12 ZNF684 (E352K) Missense 17 ZNF70 (E281K) Missense 13 ZNF732 (S156*) Stop Gain 14 ZNF737 (S410del) Inframe Deletion 12

characteristic: vus


characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Generic

characteristic: NCBI submission model

characteristic: NCBI submission package

characteristic: SRA accession

text: male

text: Moderate-high

text: missing

text: Non-HISPANIC WHITE

text: APC(L779*); APC(R1450*); ASXL1(R693*); KRAS(G12D); PIK3CA(H1047R); TP53(L201*); SMAD3(V86_C89del); TMB-Low(3mut/Mb); MSS Stable

text: missing

text: Homo sapiens

text: Moderate Adenocarcinoma

text: MHNA

text: Peritoneal metastasis

text: Cancerous

text: Peritoneal metastasis

text: L35145, MHNA

text: ABCF2 (R195C) Missense 41 ADD2 (D255N) Missense 24 ADH7 (A318S) Missense 22 AFF1 (H124R) Missense 5 AMER1 (E219*) Stop Gain 49 ANK3 (A713T) Missense 22 ANKRD11 (T150M) Missense 21 AP3B2 (V908M) Missense 35 APOH (T149M) Missense 22 ARC (E276K) Missense 17 ARHGAP30 (R393W) Missense 22 ASCL5 (R12Q) Missense 23 BNIPL (R309W) Missense 24 BOD1L1 (S683L) Missense 22 C17orf47 (R242S) Missense 24 C17orf74 (P145L) Missense 35 C2orf16 (R242Q) Missense 22 C2orf71 (P908T) Missense 21 C6orf163 (K102I) Missense 22 C9orf92 (G23A) Missense 29 CACNG3 (V76M) Missense 20 CAMP (I32T) Missense 22 CASD1 (A658T) Missense 34 CCDC148 (T144P) Missense 24 CDKL4 (L220I) Missense 21 CLVS2 (A73V) Missense 20 COL22A1 (G112R) Missense 15 CTSV (V228G) Missense 26 CUL1 (E439K) Missense 34 DAZL (A2V) Missense 21 DCAF13 (G580E) Missense 44 DCLK1 (R233C) Missense 20 DGKH (P683L) Missense 35 DMXL1 (L1948V) Missense 22 DRD2 (A420T) Missense 22 ELFN1 (T373M) Missense 20 EPPK1 (L2161*) Stop Gain 48 FAM35A (H513L) Missense 25 FBXL7 (P93L) Missense 31 FGF17 (R72H) Missense 24 FGF22 (R102C) Missense 26 FLG (H630Y) Missense 22 GABBR1 (R126Q) Missense 24 GNB2L1 (S115del) Inframe Deletion 9 H2AFY2 (E222K) Missense 14 HECW1 (R32*) Stop Gain 18 HPS3 (R530Q) Missense 21 IGDCC4 (A925V) Missense 30 KIF9 (E645V) Missense 22 KIRREL (H611L) Missense 21 KL (S742F) Missense 40 LATS2 (G200S) Missense 37 LHX6 (D375N) Missense 23 LRFN2 (G415R) Missense 23 LZTS3 (R10H) Missense 27 MAP1LC3A (E40K) Missense 25 MCF2 (Q888*) Stop Gain 43 MRPL10 (R123*) Stop Gain 23 NCKAP5 (T1564fs) Frameshift 23 NIN (K503fs) Frameshift 20 NPAP1 (R121H) Missense 34 NPFFR2 (L225F) Missense 22 NPY (G11R) Missense 17 OR2F2 (H89N) Missense 16 OTOP3 (A31V) Missense 25 OTUD5 (I398V) Missense 8 OTUD6A (C152R) Missense 47 PCCB (T234M) Missense 22 PCNXL3 (P728S) Missense 20 PIM3 (V316M) Missense 23 PMS1 (T926S) Missense 23 POLR3B (R340Q) Missense 22 PROM1 (P336S) Missense 23 ROBO1 (V1444M) Missense 25 RP11- 613M10.9 (Q42fs) Frameshift 18 RYR1 (D1027A) Missense 22 SHB (Q42fs) Frameshift 18 SLC25A4 (A90V) Missense 18 SPIC (N146fs) Frameshift 24 SUPT20H (R759Q) Missense 17 SYP (V205M) Missense 42 TADA1 (R69C) Missense 16 TGFB2 (N302fs) Frameshift 21 THAP11 (Q132dup) Inframe Insertion 12 TIMP3 (R107H) Missense 24 TMEM229A (S89C) Missense 21 TMSB4X (I10del) Inframe Deletion 37 TNRC6B (W858*) Stop Gain 25 TRPC4 (G110R) Missense 16 TTLL6 (P716A) Missense 24 TTN (R35174H) Missense 22 UAP1 (N284fs) Frameshift 20 WDR17 (L1042I) Missense 18 WNT4 (V97I) Missense 25 XYLT2 (R70Q) Missense 22 ZBBX (A427D) Missense 22 ZC3H3 (S593F) Missense 47 ZFP36L2 (A340fs) Frameshift 15 ZFP57 (G255S) Missense 23 ZFYVE20 (R538P) Missense 22 ZNF131 (N364S) Missense 20 ZNF578 (I476V) Missense 22ROBO1 (V1444M) Missense 25 RP11- 613M10.9 (Q42fs) Frameshift 18 RYR1 (D1027A) Missense 22 SHB (Q42fs) Frameshift 18 SLC25A4 (A90V) Missense 18 SPIC (N146fs) Frameshift 24 SUPT20H (R759Q) Missense 17 SYP (V205M) Missense 42 TADA1 (R69C) Missense 16 TGFB2 (N302fs) Frameshift 21 THAP11 (Q132dup) Inframe Insertion 12 TIMP3 (R107H) Missense 24 TMEM229A (S89C) Missense 21 TMSB4X (I10del) Inframe Deletion 37 TNRC6B (W858*) Stop Gain 25 TRPC4 (G110R) Missense 16 TTLL6 (P716A) Missense 24 TTN (R35174H) Missense 22 UAP1 (N284fs) Frameshift 20 WDR17 (L1042I) Missense 18 WNT4 (V97I) Missense 25 XYLT2 (R70Q) Missense 22 ZBBX (A427D) Missense 22 ZC3H3 (S593F) Missense 47 ZFP36L2 (A340fs) Frameshift 15 ZFP57 (G255S) Missense 23 ZFYVE20 (R538P) Missense 22 ZNF131 (N364S) Missense 20 ZNF578 (I476V) Missense 22


text: live

text: Generic

text: female

characteristic: Sex

characteristic: age

text: Normal

characteristic: clinical diagnosis

text: missing

text: Non-HISPANIC WHITE

characteristic: ethnicity

text: missing

text: Homo sapiens

characteristic: organism

text: Normal Appendix

characteristic: pathology

text: Normal Appendix

text: Benign Appendix

characteristic: pathology 3

text: Normal

text: Normal Appendix

text: Normal Appendix

text: Control

text: Normal Appendix

text: L49294, normal